Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Serious mental illnesses are associated with increased risk of cardiometabolic comorbidities. The objective of this study was to evaluate the prevalence of cardiometabolic comorbidity and its association with hospitalization outcomes and costs among inpatients with schizophrenia or bipolar disorder. This retrospective database analysis reviewed patients with an inpatient diagnosis of schizophrenia or bipolar disorder from the Premier Perspective® Database (4/1/2010–6/30/2012). Patients were categorized into 4 cohorts based on the number of ICD-9-CM cardiometabolic comorbidities (i.e., 0, 1, 2, or 3+). Outcomes included length of stay, mortality during the index hospitalization, healthcare costs, and 30-day all-cause readmission rates. Of 57,506 patients with schizophrenia, 66.1% had at least one cardiometabolic comorbidity; 39.3% had two or more comorbidities. Of 124,803 patients with bipolar disorder, 60.5% had at least one cardiometabolic comorbidity; 33.4% had two or more. Average length of stay was 8.5 (for patients with schizophrenia) and 5.2 (for patients with bipolar disorder) days. Each additional cardiometabolic comorbidity was associated with an increase in length of stay for patients with bipolar disorder ( p < .001) but not for patients with schizophrenia. Mortality rates during the index hospitalization were 1.2% (schizophrenia) and .7% (bipolar disorder). Each additional cardiometabolic comorbidity was associated with a significant increase in mortality for patients with bipolar disorder (OR 1.218, p < .001), and a numerical increase in mortality for patients with schizophrenia (OR 1.014, p = .727). Patients with more cardiometabolic comorbidities were more likely to have a 30-day readmission (schizophrenia = 9–13%; bipolar disorder = 7–12%), and to incur higher costs (schizophrenia = $10,606–15,355; bipolar disorder = $7126–13,523) (all p < .01). Over 60% of inpatients with schizophrenia or bipolar disorder had cardiometabolic comorbidities. Greater cardiometabolic comorbidity burden was associated with an increased likelihood of readmission and higher costs among patients with schizophrenia or bipolar disorder, and an increase in length of stay and mortality for patients with bipolar disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rehospitalizations among Patients in the Medicare Fee-for-Service Program
Jencks, S. F., Williams, M. V., & Coleman, E. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0803563 · Cited by 5,164
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 3×
“Complicating the inherent higher risk of cardiometabolic comorbidities in patients with schizophrenia or bipolar disorder, atypical antipsychotics, which are standard pharmacological treatment for schizophrenia and many patients with bipolar disorder, can exacerbate patients’ risk of cardiometabolic disease [13].”
BackgroundPremature Mortality Among Adults With Schizophrenia in the United States
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1737 · Cited by 1,083
Nordentoft, M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Laursen, T. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055176 · Cited by 778 · cited 1×
“Compounding the psychiatric disability in schizophrenia and bipolar disorder, a growing literature suggests that physical comorbidities in this population reduce life expectancy by as much as 10–25 years and double the risk of premature mortality compared to the general population [7].”
BackgroundComorbidities and Mortality in Bipolar Disorder: A Swedish National Cohort Study
Crump, C., Sundquist, K., Winkleby, M. A., & Sundquist, J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1394 · Cited by 677 · cited 1×
“7 times the rate of diabetes [3] than the general population.”
BackgroundVancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
Self-citationCorrell, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Self-citation
Cited by
John, A., McGregor, J., Jones, I., Lee, S. C., Walters, J. T. R., Owen, M. J., O'Donovan, M., DelPozo-Banos, M., Berridge, D., & Lloyd, K. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.04.009 · Cited by 190
“causes in both inpatient and community settings (Bushe et al., 2010; Copeland et al., 2009; Correll et al., 2017; Jayatilleke et al., 2017; Olfson et al., 2015; Osborn et al., 2007).”
The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review
Bessonova, L., Ogden, K., Doane, M. J., O'Sullivan, A. K., & Tohen, M. (2020) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s259338 · Cited by 147
“Those with one or more cardiometabolic conditions (vs none) had an increased likelihood of hospital readmission in the 30 days post-discharge, higher costs, longer lengths of stay, and higher in-hospital mortality.(50) Centorrino et al reported that individuals with BD had significantly more metabolic comorbidities th…”
BackgroundTorsvik, A., Brattbakk, H.-R., Trentani, A., Holdhus, R., Stansberg, C., Bartz-Johannessen, C. A., Hughes, T., Steen, N. E., Melle, I., Djurovic, S., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02442-1 · Cited by 21
“A diagnosis of SCZ or BD is associated with 8–14 years shorter life expectancy than the average population [5] and an increased risk of cardiovascular disease, respiratory diseases and infections [6].”
Background
Metadata
- Authors
- Correll, C. U., Ng-Mak, D. S., Stafkey-Mailey, D., Farrelly, E., Rajagopalan, K., & Loebel, A.
- Venue
- Annals of General Psychiatry
- Published
- 2017-02-10
- Volume
- 16
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1744-859X (ISSN-L)
- OpenAlex
- W2586669042
- Cited by
- 79
- References
- 14
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. https://app.cochat.ai/papers/10.1186/s12991-017-0133-7
- The paper
- Correll, C. U., Ng-Mak, D. S., Stafkey-Mailey, D., Farrelly, E., Rajagopalan, K., & Loebel, A. (2017). Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Annals of General Psychiatry. https://doi.org/10.1186/s12991-017-0133-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.